2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenIs the wash-out period almost over? Today, turnover fell to around 3.1 million shares, significantly lower than the preceding days (June 16–23) with 7–10 million shares. This could be a sign that much of the selling pressure after the warrant period is starting to subside. At the same time, we see that the price is holding well above the bottom of 7.47 kroner, despite the low turnover. This could indicate that the supply side is starting to dry up, although it is naturally too early to conclude. Technically, the stock has stabilized after the sharp correction, and it is now moving in a consolidation phase around 7.6–7.8 kroner. A break above 7.90–8.00 kroner could give a more positive technical signal, while the support area still lies around 7.45–7.55 kroner. Fundamentally, there are several possible triggers ahead. The BIO conference is still ongoing, the STOXX effect can still generate increased interest, and the market will eventually turn its attention to upcoming PoC data and any new partnership updates. I believe the most intense wash-out period may be behind us, but it will probably require positive news or increasing buying interest before the stock gets a more lasting boost. What do you think – has the selling pressure largely subsided, or do you expect a new round of pressure?- ·1 t sittenWhat will this mean for tomorrow?
This is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins. - ·3 t sittenCircio Holding ASA ("Circio" or "the Company") announced on June 24, 2026, a research collaboration with Tcelltech GmbH ("Tcelltech"), a biotechnology company based in Mannheim, to combine circVec with Tcelltech's non-viral, non-integrating, episomal nanoSMAR DNA vector platform for next-generation engineered T-cell therapies, including in vivo CAR-T and TCR-T. The program proceeds in phases: an initial "proof-of-concept" phase comparing how strongly and how durably the technology combination drives gene expression in primary human T-cells, followed by a functional phase where CD19-targeted CAR T-cells are generated and assessed for their ability to kill tumor cells. No financial terms have been disclosed. In summary, Analyst Group views the Telltech collaboration as a technically coherent addition to Circio's in vivo cell therapy portfolio. The high-payload non-viral nanoSMAR format solves the delivery problem, while circVec solves the expression durability problem. These are complementary bottlenecks that together can form the basis for a differentiated in vivo CAR-T/TCR-T approach. That said, the program is still at an early preclinical stage with no financial terms disclosed. The cell therapy track also still represents a more long-term option layer rather than a short-term value driver. All in all, Analyst Group assesses that the collaboration adds another credible partner to Circle Vec's delivery network and gradually supports the platform's licensing appeal. Read Analyst Group's comment here Comment PublisherThis is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenIs the wash-out period almost over? Today, turnover fell to around 3.1 million shares, significantly lower than the preceding days (June 16–23) with 7–10 million shares. This could be a sign that much of the selling pressure after the warrant period is starting to subside. At the same time, we see that the price is holding well above the bottom of 7.47 kroner, despite the low turnover. This could indicate that the supply side is starting to dry up, although it is naturally too early to conclude. Technically, the stock has stabilized after the sharp correction, and it is now moving in a consolidation phase around 7.6–7.8 kroner. A break above 7.90–8.00 kroner could give a more positive technical signal, while the support area still lies around 7.45–7.55 kroner. Fundamentally, there are several possible triggers ahead. The BIO conference is still ongoing, the STOXX effect can still generate increased interest, and the market will eventually turn its attention to upcoming PoC data and any new partnership updates. I believe the most intense wash-out period may be behind us, but it will probably require positive news or increasing buying interest before the stock gets a more lasting boost. What do you think – has the selling pressure largely subsided, or do you expect a new round of pressure?
- ·1 t sittenWhat will this mean for tomorrow?This is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins.
- ·3 t sittenCircio Holding ASA ("Circio" or "the Company") announced on June 24, 2026, a research collaboration with Tcelltech GmbH ("Tcelltech"), a biotechnology company based in Mannheim, to combine circVec with Tcelltech's non-viral, non-integrating, episomal nanoSMAR DNA vector platform for next-generation engineered T-cell therapies, including in vivo CAR-T and TCR-T. The program proceeds in phases: an initial "proof-of-concept" phase comparing how strongly and how durably the technology combination drives gene expression in primary human T-cells, followed by a functional phase where CD19-targeted CAR T-cells are generated and assessed for their ability to kill tumor cells. No financial terms have been disclosed. In summary, Analyst Group views the Telltech collaboration as a technically coherent addition to Circio's in vivo cell therapy portfolio. The high-payload non-viral nanoSMAR format solves the delivery problem, while circVec solves the expression durability problem. These are complementary bottlenecks that together can form the basis for a differentiated in vivo CAR-T/TCR-T approach. That said, the program is still at an early preclinical stage with no financial terms disclosed. The cell therapy track also still represents a more long-term option layer rather than a short-term value driver. All in all, Analyst Group assesses that the collaboration adds another credible partner to Circle Vec's delivery network and gradually supports the platform's licensing appeal. Read Analyst Group's comment here Comment PublisherThis is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenIs the wash-out period almost over? Today, turnover fell to around 3.1 million shares, significantly lower than the preceding days (June 16–23) with 7–10 million shares. This could be a sign that much of the selling pressure after the warrant period is starting to subside. At the same time, we see that the price is holding well above the bottom of 7.47 kroner, despite the low turnover. This could indicate that the supply side is starting to dry up, although it is naturally too early to conclude. Technically, the stock has stabilized after the sharp correction, and it is now moving in a consolidation phase around 7.6–7.8 kroner. A break above 7.90–8.00 kroner could give a more positive technical signal, while the support area still lies around 7.45–7.55 kroner. Fundamentally, there are several possible triggers ahead. The BIO conference is still ongoing, the STOXX effect can still generate increased interest, and the market will eventually turn its attention to upcoming PoC data and any new partnership updates. I believe the most intense wash-out period may be behind us, but it will probably require positive news or increasing buying interest before the stock gets a more lasting boost. What do you think – has the selling pressure largely subsided, or do you expect a new round of pressure?
- ·1 t sittenWhat will this mean for tomorrow?This is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins.
- ·3 t sittenCircio Holding ASA ("Circio" or "the Company") announced on June 24, 2026, a research collaboration with Tcelltech GmbH ("Tcelltech"), a biotechnology company based in Mannheim, to combine circVec with Tcelltech's non-viral, non-integrating, episomal nanoSMAR DNA vector platform for next-generation engineered T-cell therapies, including in vivo CAR-T and TCR-T. The program proceeds in phases: an initial "proof-of-concept" phase comparing how strongly and how durably the technology combination drives gene expression in primary human T-cells, followed by a functional phase where CD19-targeted CAR T-cells are generated and assessed for their ability to kill tumor cells. No financial terms have been disclosed. In summary, Analyst Group views the Telltech collaboration as a technically coherent addition to Circio's in vivo cell therapy portfolio. The high-payload non-viral nanoSMAR format solves the delivery problem, while circVec solves the expression durability problem. These are complementary bottlenecks that together can form the basis for a differentiated in vivo CAR-T/TCR-T approach. That said, the program is still at an early preclinical stage with no financial terms disclosed. The cell therapy track also still represents a more long-term option layer rather than a short-term value driver. All in all, Analyst Group assesses that the collaboration adds another credible partner to Circle Vec's delivery network and gradually supports the platform's licensing appeal. Read Analyst Group's comment here Comment PublisherThis is primarily positive, but early-stage news for Circio Holding ASA. What the collaboration actually means The collaboration with Tcelltech GmbH combines two technologies that address different challenges in in vivo cell therapy: * Tcelltech's nanoSMAR platform is intended to deliver genetic material to T-cells without viruses and without integration into the genome. * Circio's circVec platform is intended to ensure more robust and long-lasting gene expression after the material has been delivered. The goal is to develop next-generation CAR-T and TCR-T therapies, including treatments that can potentially be given directly in the body ("in vivo") without extensive cell manipulation outside the patient. Why the market might like this From a strategic perspective, this strengthens Circio's story as a platform provider: 1. New partner validation * Yet another external party chooses to test circVec in its technology. * More partnerships can make it easier to argue that the technology has broad application. 2. Complementary technology * Delivery and expression duration are two of the biggest challenges in gene therapy and cell therapy. * If nanoSMAR solves delivery and circVec solves duration, the combination could become interesting. 3. Expands cell therapy initiative * Circio has already announced collaborations in in vivo cell therapy with other parties earlier in 2026. * This builds further on that strategy. What investors should remember This is still: * Early preclinical research. * No published data yet. * No disclosed financial terms. * No license agreement or commercialization in place. Analyst Group therefore describes the project more as a long-term option than a short-term value driver. It is only if the proof-of-concept data become strong that the market can begin to price in greater commercial value. My assessment For a shareholder in Circio, this is probably a moderately positive message: * It increases the scientific and industrial validation of circVec. * It adds yet another partner to the ecosystem around the technology. * However, it does not change the company's fundamental risk profile in the short term, as everything is still preclinical and without known revenues from the collaboration. The most interesting question going forward is therefore not the agreement itself, but whether the first proof-of-concept phase shows that the combination actually provides stronger and more lasting gene expression in human T-cells than current alternatives. That is where the real value creation begins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt